$COEP
Coeptis Therapeutics Holdings, Inc.

2023 Q3 Form 10-Q Financial Statement

#000168316823005600 Filed on August 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $2.828M $3.218M $9.749M
YoY Change -48.5% -66.99% 277.73%
% of Gross Profit
Research & Development $4.983M $377.0K $0.00
YoY Change 23758.62%
% of Gross Profit
Depreciation & Amortization $250.0K $250.3K $250.3K
YoY Change -0.01% 29351.76%
% of Gross Profit
Operating Expenses $7.831M $3.638M $852.8K
YoY Change 1340.5% 326.59% 447.76%
Operating Profit -$7.831M -$3.638M -$9.813M
YoY Change 1340.49% -62.93% 6202.82%
Interest Expense $19.80K $42.64K $49.43K
YoY Change -86.42% -13.74% 2515.34%
% of Operating Profit
Other Income/Expense, Net $1.571M $525.0K $598.6K
YoY Change 1593.1% -12.3% -136.28%
Pretax Income -$6.261M -$3.113M -$204.8K
YoY Change 1952.02% 1420.41% -88.65%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.261M -$3.113M -$204.8K
YoY Change 1952.04% 1420.41% -88.65%
Net Earnings / Revenue
Basic Earnings Per Share -$0.23 -$0.14 -$0.75
Diluted Earnings Per Share -$0.23 -$0.14 -$32.50K
COMMON SHARES
Basic Shares Outstanding 25.14M shares 21.44M shares 13.02M shares
Diluted Shares Outstanding 26.65M shares 21.81M shares 13.02M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.410M $3.245M $84.15K
YoY Change 10095.23% 3755.98% -86.94%
Cash & Equivalents $1.412M $3.245M $2.378M
Short-Term Investments
Other Short-Term Assets $210.0K $202.5K $38.80K
YoY Change 1125.2% 421.86% -17.08%
Inventory $0.00
Prepaid Expenses $208.1K $202.5K
Receivables $0.00 $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $4.120M $3.797M $123.0K
YoY Change 13206.02% 2988.48% -82.21%
LONG-TERM ASSETS
Property, Plant & Equipment $11.62K $11.92K $91.18K
YoY Change -86.92% 71.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $32.99M
YoY Change -56.45%
Other Assets $3.010M $3.308M
YoY Change
Total Long-Term Assets $3.050M $3.358M $32.99M
YoY Change -90.83% -89.82% -56.45%
TOTAL ASSETS
Total Short-Term Assets $4.120M $3.797M $123.0K
Total Long-Term Assets $3.050M $3.358M $32.99M
Total Assets $7.171M $7.156M $33.11M
YoY Change -78.47% -78.39% -56.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $482.0K $395.2K $948.9K
YoY Change -65.58% -58.35% 2655.28%
Accrued Expenses $298.3K $247.3K $325.1K
YoY Change -23.92% 49.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $830.0K $1.850M $3.663M
YoY Change -49.49% 388.62%
Total Short-Term Liabilities $1.616M $2.514M $948.9K
YoY Change -14.68% 164.92% 2655.28%
LONG-TERM LIABILITIES
Long-Term Debt $150.0K $150.0K $0.00
YoY Change
Other Long-Term Liabilities $390.0K $2.002M $3.153M
YoY Change -85.56% -36.5% -69.65%
Total Long-Term Liabilities $543.1K $2.152M $3.153M
YoY Change -79.89% -31.74% -69.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.616M $2.514M $948.9K
Total Long-Term Liabilities $543.1K $2.152M $3.153M
Total Liabilities $2.159M $4.666M $4.102M
YoY Change -53.0% 13.75% -60.64%
SHAREHOLDERS EQUITY
Retained Earnings -$82.98M -$76.72M
YoY Change 1680.87%
Common Stock $3.299K $2.440K
YoY Change -86.8%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $0.00 $0.00
YoY Change
Treasury Stock Shares
Shareholders Equity $5.012M $2.490M $29.01M
YoY Change
Total Liabilities & Shareholders Equity $7.171M $7.156M $33.11M
YoY Change -78.47% -78.39% -56.69%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$6.261M -$3.113M -$204.8K
YoY Change 1952.04% 1420.41% -88.65%
Depreciation, Depletion And Amortization $250.0K $250.3K $250.3K
YoY Change -0.01% 29351.76%
Cash From Operating Activities -$1.960M -$1.903M -$256.0K
YoY Change 2686.86% 643.2% 109.53%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $350.0K -$350.0K $42.83M
YoY Change -362.51% -100.82%
Cash From Investing Activities $350.0K -$350.0K $42.83M
YoY Change -362.51% -100.82% -5810.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $173.8K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -220.0K 3.391M -42.65M
YoY Change -265.0% -107.95%
NET CHANGE
Cash From Operating Activities -1.960M -1.903M -256.0K
Cash From Investing Activities 350.0K -350.0K 42.83M
Cash From Financing Activities -220.0K 3.391M -42.65M
Net Change In Cash -1.830M 1.138M -82.22K
YoY Change 2502.02% -1484.07% -32.72%
FREE CASH FLOW
Cash From Operating Activities -$1.960M -$1.903M -$256.0K
Capital Expenditures $0.00
Free Cash Flow -$256.0K
YoY Change -70.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001759186
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39669
dei Entity Registrant Name
EntityRegistrantName
COEPTIS THERAPEUTICS HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1465952
dei Entity Address Address Line1
EntityAddressAddressLine1
105 Bradford Rd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 420
dei Entity Address City Or Town
EntityAddressCityOrTown
Wexford
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
15090
dei City Area Code
CityAreaCode
724
dei Local Phone Number
LocalPhoneNumber
934-6467
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25141036 shares
CY2023Q2 us-gaap Cash
Cash
3244812 usd
CY2022Q4 us-gaap Cash
Cash
3791302 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8075 usd
CY2023Q2 us-gaap Notes Receivable Net
NotesReceivableNet
350000 usd
CY2022Q4 us-gaap Notes Receivable Net
NotesReceivableNet
0 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
202476 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
142356 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
3797288 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3941733 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25237 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25237 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13313 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12695 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11924 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12542 usd
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
253333 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
348333 usd
CY2023Q2 coep License Right Net Of Accumulated Amortization
LicenseRightNetOfAccumulatedAmortization
3054167 usd
CY2022Q4 coep License Right Net Of Accumulated Amortization
LicenseRightNetOfAccumulatedAmortization
3554167 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
38987 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
58914 usd
CY2023Q2 us-gaap Other Assets
OtherAssets
3346487 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
3961414 usd
CY2023Q2 us-gaap Assets
Assets
7155699 usd
CY2022Q4 us-gaap Assets
Assets
7915689 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
395232 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
99021 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
247341 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
181998 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
1850000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1500000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21276 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
41618 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2513849 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1822637 usd
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
150000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
150000 usd
CY2023Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1987500 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1125000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14723 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14723 usd
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2152223 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1289723 usd
CY2023Q2 us-gaap Liabilities
Liabilities
4666072 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3112360 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24396036 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24396036 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19566839 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19566839 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
2440 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1957 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
79208185 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
70541095 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76720998 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65739723 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2489627 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4803329 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7155699 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7915689 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
CY2022Q2 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
377040 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
402780 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3218055 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9744976 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9641677 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25460292 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
300 usd
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4052 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
300 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4052 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
42636 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
63826 usd
us-gaap Interest Expense
InterestExpense
74053 usd
us-gaap Interest Expense
InterestExpense
119644 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
3638031 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
9812854 usd
us-gaap Operating Expenses
OperatingExpenses
10118810 usd
us-gaap Operating Expenses
OperatingExpenses
25583988 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3638031 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9812854 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10118810 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-25583988 usd
CY2023Q2 us-gaap Royalty Expense
RoyaltyExpense
-0 usd
CY2022Q2 us-gaap Royalty Expense
RoyaltyExpense
5000 usd
us-gaap Royalty Expense
RoyaltyExpense
-0 usd
us-gaap Royalty Expense
RoyaltyExpense
5000 usd
CY2023Q2 us-gaap Other Income
OtherIncome
0 usd
CY2022Q2 us-gaap Other Income
OtherIncome
0 usd
us-gaap Other Income
OtherIncome
35 usd
us-gaap Other Income
OtherIncome
0 usd
CY2023Q2 coep Gain Loss On Change In Fair Value Of Derivative Liability Warrants
GainLossOnChangeInFairValueOfDerivativeLiabilityWarrants
525000 usd
CY2022Q2 coep Gain Loss On Change In Fair Value Of Derivative Liability Warrants
GainLossOnChangeInFairValueOfDerivativeLiabilityWarrants
0 usd
coep Gain Loss On Change In Fair Value Of Derivative Liability Warrants
GainLossOnChangeInFairValueOfDerivativeLiabilityWarrants
-862500 usd
coep Gain Loss On Change In Fair Value Of Derivative Liability Warrants
GainLossOnChangeInFairValueOfDerivativeLiabilityWarrants
0 usd
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
15017 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3393542 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
525000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10017 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-862465 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3398542 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3113031 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9802837 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10981275 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28982530 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3113031 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9802837 usd
us-gaap Net Income Loss
NetIncomeLoss
-10981275 usd
us-gaap Net Income Loss
NetIncomeLoss
-28982530 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.26
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21808563 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21808563 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13022492 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13022492 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21080395 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21080395 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12815445 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12815445 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2350634 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1266000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3540000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
110000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
10841695 usd
CY2022Q1 coep Warrants Issued For Extinguishment Of Debt
WarrantsIssuedForExtinguishmentOfDebt
3408559 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-19179693 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2337195 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
685485 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
180000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
382500 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
8278691 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9802837 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2061034 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4803329 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3116814 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1111706 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
122391 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7868244 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1285996 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
351000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
811500 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
113301 usd
CY2023Q2 coep Issuance Of Common Stock And Warrants Net Of Issuance Costs
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
3040861 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3113031 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2489627 usd
us-gaap Net Income Loss
NetIncomeLoss
-10981275 usd
us-gaap Net Income Loss
NetIncomeLoss
-28982530 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
500618 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
500692 usd
coep Gainloss On Change In Value Of Warrant Liability
GainlossOnChangeInValueOfWarrantLiability
862500 usd
coep Gainloss On Change In Value Of Warrant Liability
GainlossOnChangeInValueOfWarrantLiability
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
235692 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
3467814 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
3720000 usd
coep Warrants Issued For Extinguishment Of Debt Cash Flow
WarrantsIssuedForExtinguishmentOfDebtCashFlow
0 usd
coep Warrants Issued For Extinguishment Of Debt Cash Flow
WarrantsIssuedForExtinguishmentOfDebtCashFlow
3408559 usd
coep Warrants Issued For Services
WarrantsIssuedForServices
1923206 usd
coep Warrants Issued For Services
WarrantsIssuedForServices
19120386 usd
coep Debt Discount From Modification Of Debt
DebtDiscountFromModificationOfDebt
0 usd
coep Debt Discount From Modification Of Debt
DebtDiscountFromModificationOfDebt
-4298 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8075 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-34880 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-0 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-415 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
1043 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
296211 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
134372 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
65343 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
106526 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3587351 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1995250 usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
350000 usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
-0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-350000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
350000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
coep Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
-3040861 usd
coep Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
-0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
-0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
250000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1951486 usd
coep Shares Issued For Cash For Conversion Warrants
SharesIssuedForCashForConversionWarrants
0 usd
coep Shares Issued For Cash For Conversion Warrants
SharesIssuedForCashForConversionWarrants
490000 usd
coep Cash Received For Stock Subscription
CashReceivedForStockSubscription
0 usd
coep Cash Received For Stock Subscription
CashReceivedForStockSubscription
2500 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3390861 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2193986 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-546490 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
198736 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3791302 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2179558 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3244812 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2378294 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zJGcWNnspAPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zroQ22tTVhLa">Use of Estimates</span> –</b> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76720998 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
1687 usd
CY2023Q2 coep Long Term Debt Maturities Repayments Of Principal After Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour
148313 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
150000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0 usd
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24396036 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24396036 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19566839 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19566839 shares
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
3040585 usd
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1951463 usd
us-gaap Partners Capital Account Distributions
PartnersCapitalAccountDistributions
0 usd
us-gaap Partners Capital Account Distributions
PartnersCapitalAccountDistributions
0 usd
CY2023Q2 coep Warrants Issued
WarrantsIssued
2150000 shares
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
0 usd
CY2022Q2 us-gaap Treasury Stock Value
TreasuryStockValue
0 usd
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1206749 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
22500 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
22500 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
22500 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
18750 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
41250 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5251 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
35999 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
38987 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21276 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14723 usd
CY2023Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
4000000 shares
CY2023Q2 coep Cash Payment
CashPayment
350000 usd
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0 usd
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0 usd
CY2022Q2 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0 usd
CY2023Q2 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
350000 usd
CY2023Q2 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
461905 usd

Files In Submission

Name View Source Status
0001683168-23-005600-index-headers.html Edgar Link pending
0001683168-23-005600-index.html Edgar Link pending
0001683168-23-005600.txt Edgar Link pending
0001683168-23-005600-xbrl.zip Edgar Link pending
coep-20230630.xsd Edgar Link pending
coeptis_ex3101.htm Edgar Link pending
coeptis_ex3102.htm Edgar Link pending
coeptis_ex3201.htm Edgar Link pending
coeptis_ex3202.htm Edgar Link pending
coeptis_i10q-063023.htm Edgar Link pending
coep-20230630_def.xml Edgar Link unprocessable
coep-20230630_cal.xml Edgar Link unprocessable
coep-20230630_lab.xml Edgar Link unprocessable
coep-20230630_pre.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
coeptis_i10q-063023_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable